A director at Paycom Software Inc sold 2,192 shares at 165.849USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
As a leader in PC peripherals, Logitech is perfectly positioned to benefit from the PC replacement cycle (acceleration in volumes in Q3 and knock-on effect on peripherals) and the medium/long-term outlook for gaming (underestimated in our view, steady market share gains). This should translate into a solid financial performance (EPS CAGR 2025-28e of 14%) and trigger an upward revision phase (we are ~11% > css on FY 2027-28e EPS). We are initiating coverage at Outperform with a target price of CH...
En tant que leader sur les périphériques PC, Logitech est parfaitement positionné pour bénéficier du cycle de remplacement PC (accélération des volumes au T3 et effet d’entrainement sur les périphériques) et des perspectives du gaming à moyen/long terme (sous-estimées selon nous, gains de PdM réguliers). Cela devrait se traduire par une solide performance financière (TMVA BPA 25-28e de 14%) et enclencher une phase de révisions en hausse (nous sommes ~11% > au css sur les BPA FY 27-28e). Nous ini...
Codexis Announces Signing of Lease for GMP Manufacturing Facility REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California. The multi-purpose facility will allow Codexis to expand its internal capabilities into GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform. The company expects to begin modific...
Codexis Reports Third Quarter 2025 Financial Results Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced financial results for the third quarter ended September 30, 2025. The company also provided a business update that includes signing a $37.8m Supply Ass...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.